BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 27197187)

  • 1. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
    Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
    Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.
    Qu Z; Sun F; Zhou J; Li L; Shapiro SD; Xiao G
    Cancer Res; 2015 Aug; 75(16):3209-15. PubMed ID: 26122841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL22 Promotes
    Khosravi N; Caetano MS; Cumpian AM; Unver N; De la Garza Ramos C; Noble O; Daliri S; Hernandez BJ; Gutierrez BA; Evans SE; Hanash S; Alekseev AM; Yang Y; Chang SH; Nurieva R; Kadara H; Chen J; Ostrin EJ; Moghaddam SJ
    Cancer Immunol Res; 2018 Jul; 6(7):788-797. PubMed ID: 29764837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
    Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
    Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.
    Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM
    Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.
    Caetano MS; Hassane M; Van HT; Bugarin E; Cumpian AM; McDowell CL; Cavazos CG; Zhang H; Deng S; Diao L; Wang J; Evans SE; Behrens C; Wistuba II; Fuqua SAW; Lin H; Stabile LP; Watowich SS; Kadara H; Moghaddam SJ
    Nat Commun; 2018 Nov; 9(1):4589. PubMed ID: 30389925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
    Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor.
    Njatcha C; Farooqui M; Almotlak AA; Siegfried JM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):735-746. PubMed ID: 32655003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.
    Peng D; Tanikawa T; Li W; Zhao L; Vatan L; Szeliga W; Wan S; Wei S; Wang Y; Liu Y; Staroslawska E; Szubstarski F; Rolinski J; Grywalska E; Stanisławek A; Polkowski W; Kurylcio A; Kleer C; Chang AE; Wicha M; Sabel M; Zou W; Kryczek I
    Cancer Res; 2016 Jun; 76(11):3156-65. PubMed ID: 27197152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.
    Moghaddam SJ; Li H; Cho SN; Dishop MK; Wistuba II; Ji L; Kurie JM; Dickey BF; Demayo FJ
    Am J Respir Cell Mol Biol; 2009 Apr; 40(4):443-53. PubMed ID: 18927348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis.
    Ochoa CE; Mirabolfathinejad SG; Ruiz VA; Evans SE; Gagea M; Evans CM; Dickey BF; Moghaddam SJ
    Cancer Prev Res (Phila); 2011 Jan; 4(1):51-64. PubMed ID: 21098042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.
    Deng S; Ramos-Castaneda M; Velasco WV; Clowers MJ; Gutierrez BA; Noble O; Dong Y; Zarghooni M; Alvarado L; Caetano MS; Yang S; Ostrin EJ; Behrens C; Wistuba II; Stabile LP; Kadara H; Watowich SS; Moghaddam SJ
    Carcinogenesis; 2020 Nov; 41(11):1529-1542. PubMed ID: 32603404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
    Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
    Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
    Jing B; Wang T; Sun B; Xu J; Xu D; Liao Y; Song H; Guo W; Li K; Hu M; Zhang S; Ling J; Kuang Y; Zhang T; Zhou BP; Yao F; Deng J
    Cancer Res; 2020 Feb; 80(4):784-797. PubMed ID: 31848193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.
    Hervé V; Rabbe N; Guilleminault L; Paul F; Schlick L; Azzopardi N; Duruisseaux M; Fouquenet D; Montharu J; Redini F; Paintaud G; Lemarié E; Cadranel J; Wislez M; Heuzé-Vourc'h N
    MAbs; 2014; 6(6):1638-48. PubMed ID: 25484066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs.
    Zaynagetdinov R; Sherrill TP; Gleaves LA; Hunt P; Han W; McLoed AG; Saxon JA; Tanjore H; Gulleman PM; Young LR; Blackwell TS
    Oncotarget; 2016 Feb; 7(5):5470-82. PubMed ID: 26756215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
    Song L; Smith MA; Doshi P; Sasser K; Fulp W; Altiok S; Haura EB
    J Thorac Oncol; 2014 Jul; 9(7):974-982. PubMed ID: 24922005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
    Grabner B; Schramek D; Mueller KM; Moll HP; Svinka J; Hoffmann T; Bauer E; Blaas L; Hruschka N; Zboray K; Stiedl P; Nivarthi H; Bogner E; Gruber W; Mohr T; Zwick RH; Kenner L; Poli V; Aberger F; Stoiber D; Egger G; Esterbauer H; Zuber J; Moriggl R; Eferl R; Győrffy B; Penninger JM; Popper H; Casanova E
    Nat Commun; 2015 Mar; 6():6285. PubMed ID: 25734337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
    Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
    Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.